Anticoagulation of patients with cirrhosis and portal vein thrombosis (PVT) has been shown to lead to thrombosis regression and even resolution; however, bleeding risk is a concern in this population. In the current systematic review and meta-analysis, researchers assessed outcomes of anticoagulation in patients with cirrhosis and PVT..